Xilio Therapeutics (XLO) Competitors $1.28 +0.34 (+36.46%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends XLO vs. NBTX, MCRB, PBYI, GALT, MNPR, PEPG, TELO, ENTA, ATOS, and IFRXShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Nanobiotix (NBTX), Seres Therapeutics (MCRB), Puma Biotechnology (PBYI), Galectin Therapeutics (GALT), Monopar Therapeutics (MNPR), PepGen (PEPG), Telomir Pharmaceuticals (TELO), Enanta Pharmaceuticals (ENTA), Atossa Therapeutics (ATOS), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry. Xilio Therapeutics vs. Nanobiotix Seres Therapeutics Puma Biotechnology Galectin Therapeutics Monopar Therapeutics PepGen Telomir Pharmaceuticals Enanta Pharmaceuticals Atossa Therapeutics InflaRx Xilio Therapeutics (NASDAQ:XLO) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends. Which has higher valuation & earnings, XLO or NBTX? Nanobiotix has higher revenue and earnings than Xilio Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$4.62M12.18-$76.40M-$1.72-0.74Nanobiotix$39.18M3.73-$42.97MN/AN/A Which has more risk & volatility, XLO or NBTX? Xilio Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Does the media prefer XLO or NBTX? In the previous week, Xilio Therapeutics had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Xilio Therapeutics and 3 mentions for Nanobiotix. Xilio Therapeutics' average media sentiment score of 0.67 beat Nanobiotix's score of 0.22 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is XLO or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio TherapeuticsN/A -211.50% -80.31% Nanobiotix N/A N/A N/A Does the MarketBeat Community prefer XLO or NBTX? Xilio Therapeutics received 1 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 75.00% of users gave Xilio Therapeutics an outperform vote while only 64.71% of users gave Nanobiotix an outperform vote. CompanyUnderperformOutperformXilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% NanobiotixOutperform Votes1164.71% Underperform Votes635.29% Do analysts prefer XLO or NBTX? Xilio Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 212.50%. Nanobiotix has a consensus price target of $12.00, suggesting a potential upside of 287.10%. Given Nanobiotix's higher possible upside, analysts clearly believe Nanobiotix is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nanobiotix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in XLO or NBTX? 54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 5.2% of Xilio Therapeutics shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryXilio Therapeutics and Nanobiotix tied by winning 7 of the 14 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.27M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.7410.5991.3417.19Price / Sales12.18195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book0.965.104.794.78Net Income-$76.40M$151.51M$120.07M$225.60M7 Day Performance32.12%-2.14%-1.90%-1.24%1 Month Performance39.13%-3.13%11.43%3.06%1 Year Performance140.92%11.51%30.59%16.50% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics2.8012 of 5 stars$1.28+36.5%$4.00+212.5%+155.8%$56.27M$4.62M-0.7473News CoverageGap UpHigh Trading VolumeNBTXNanobiotix2.0847 of 5 stars$3.34+0.3%$12.00+259.3%-53.3%$157.42M$36.22M0.00100News CoverageGap UpMCRBSeres Therapeutics3.3434 of 5 stars$0.92+4.9%$5.08+451.8%-14.4%$157.30M$126.33M-4.04233PBYIPuma Biotechnology3.9504 of 5 stars$3.01+4.5%$7.00+132.6%-30.0%$147.76M$243.57M6.42185Positive NewsGALTGalectin Therapeutics1.9737 of 5 stars$2.28+8.1%$11.00+382.5%-39.2%$143.10MN/A-3.149News CoverageGap DownHigh Trading VolumeMNPRMonopar Therapeutics1.975 of 5 stars$27.06+6.6%$27.33+1.0%+1,165.4%$142.82MN/A-12.8810News CoverageGap UpPEPGPepGen2.1221 of 5 stars$4.36-6.8%$13.67+213.5%-44.2%$142.14MN/A-1.1772Analyst RevisionNews CoverageHigh Trading VolumeTELOTelomir PharmaceuticalsN/A$4.75-8.7%N/AN/A$140.65MN/A0.001High Trading VolumeENTAEnanta Pharmaceuticals4.0505 of 5 stars$6.36+5.5%$19.50+206.6%-26.3%$134.79M$67.64M-1.10145ATOSAtossa Therapeutics1.5209 of 5 stars$1.06-5.4%$7.00+560.4%+32.4%$133.35MN/A-5.208IFRXInflaRx2.4025 of 5 stars$2.26-4.2%$8.00+254.0%+50.3%$133.08M$168,498.00-2.1960Analyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies NBTX Competitors MCRB Competitors PBYI Competitors GALT Competitors MNPR Competitors PEPG Competitors TELO Competitors ENTA Competitors ATOS Competitors IFRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XLO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XLO Stock Alerts